pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Teva agrees to $35 million settlement over delayed generic asthma inhalers

Aug 6, 2026·read at Endpoints ↗RegulatoryNegative

A Massachusetts federal judge approved a settlement involving Teva Pharmaceuticals and several healthcare funds.

The agreement sets the payment at $35 million to resolve the dispute.

The funds allege that Teva postponed the launch of generic versions of its asthma inhalers, which they say led to higher drug prices.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Judge signs off on Teva's $35M settlement over delayed inhaler generics”

read at Endpoints ↗
82 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
TEVA PHARMACEUTICAL INDUSTRIES LTD5
topics
Asthma2

related stories

  • Jul 17Opinion: What the 20th-century war on smog tells us about today’s wildfire smokeSTAT
  • Jul 17GSK shelves cough drug acquired in $2B dealBioPharma Dive
  • Jul 17Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to MiradorFierce Biotech
  • Jul 16Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharmaBioSpace
  • Jul 15STAT+: Bipartisan lawmakers want to require U.S. to probe reliance on foreign-made drugs, ingredientsSTAT